Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
Intrinsic Value
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ul... [ Read More ]
The intrinsic value of one
RARE
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 40.14 USD,
Ultragenyx Pharmaceutical Inc
is
hidden
.
RARE's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
RARE or that its price is influenced by factors unrelated to fundamentals.
Ultragenyx Pharmaceutical Inc's market capitalization is 3.3B USD.
RARE stock price is 40.14 USD.
RARE stock price (40.14 USD) is 44% less than its Intrinsic Value (71.94 USD).
RARE. Open DCF Valuation
RARE stock price (40.14 USD) is 44% less than its Relative Value (71.94 USD). Open Relative Valuation
RARE has upside potential of 127% compared to the average analyst price target.
Open Wall St Estimates
RARE's long-term assets (1B USD) exceed its long-term liabilties (1B USD).
RARE's Revenue has grown by 15% over the past 12 months.
RARE's Revenue has been growing by 10% per year for the last 3 years.
RARE's Revenue is forecast to grow at a rate of 27% per year over the next 3 years.
RARE's ROE (Return on Equity) has significantly decreased in the last 3 years from -24% to -340%, and is approaching profitability.
RARE's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -54% to -75%, and is approaching profitability.
RARE has negative Operating Income for the last twelve months.
RARE has negative Net Income for the last twelve months.
RARE's ROE (Return on Equity) for the past 12 months is negative and is equal to -340%.
RARE's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -75%.
RARE's short-term assets (596m USD) exceed its short-term liabilties (246m USD).
RARE has positive Gross Profit for the last twelve months.
RARE has negative Free Cash Flow for the last twelve months.
RARE has negative three-year average ROE (Return on Equity): -122%. The company is not efficient at transforming stockholders' equity into net income.
RARE has negative three-year average ROIC (Return on Invested Capital): -73%. The company is not efficient at using invested capital to generate operating income.
RARE's D/E (Debt to Equity) is very low and is equal to 0.
RARE's Altman Z-Score is very low and is equal to -3.
Valuation Backtest
Ultragenyx Pharmaceutical Inc
Run backtest to discover the historical profit from buying and selling
RARE
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
This note will be permanently deleted.
Ultragenyx Pharmaceutical Inc
Balance Sheet Decomposition
Ultragenyx Pharmaceutical Inc
| Current Assets | 596m |
| Cash & Short-Term Investments | 412.1m |
| Receivables | 100.3m |
| Other Current Assets | 83.6m |
| Non-Current Assets | 711.1m |
| Long-Term Investments | 156.6m |
| PP&E | 285.1m |
| Intangibles | 209.5m |
| Other Non-Current Assets | 60m |
| Current Liabilities | 245.6m |
| Accounts Payable | 41m |
| Accrued Liabilities | 161.9m |
| Other Current Liabilities | 42.7m |
| Non-Current Liabilities | 921.2m |
| Other Non-Current Liabilities | 921.2m |
Earnings Waterfall
Ultragenyx Pharmaceutical Inc
|
Revenue
|
442.6m
USD
|
|
Cost of Revenue
|
-50.5m
USD
|
|
Gross Profit
|
392.1m
USD
|
|
Operating Expenses
|
-972.6m
USD
|
|
Operating Income
|
-580.5m
USD
|
|
Other Expenses
|
-32.8m
USD
|
|
Net Income
|
-613.3m
USD
|
Free Cash Flow Analysis
Ultragenyx Pharmaceutical Inc
| USD | |
| Free Cash Flow | USD |
RARE Profitability Score
Profitability Due Diligence
Ultragenyx Pharmaceutical Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Ultragenyx Pharmaceutical Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
RARE Solvency Score
Solvency Due Diligence
Ultragenyx Pharmaceutical Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Ultragenyx Pharmaceutical Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RARE Price Targets Summary
Ultragenyx Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for
RARE
is 91.29 USD
with a low forecast of 48.48 USD and a high forecast of 147 USD.
Ownership
RARE Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
RARE Price
Ultragenyx Pharmaceutical Inc
| Average Annual Return | 27.28% |
| Standard Deviation of Annual Returns | 126.54% |
| Max Drawdown | -82% |
| Market Capitalization | 3.3B USD |
| Shares Outstanding | 83 133 296 |
| Percentage of Shares Shorted | 6.52% |
Company Profile
Ultragenyx Pharmaceutical Inc
Country
Industry
Market Cap
Dividend Yield
Description
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The company is headquartered in Novato, California and currently employs 1,119 full-time employees. The company went IPO on 2014-01-31. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.
Contact
IPO
Employees
Officers
The intrinsic value of one
RARE
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 40.14 USD,
Ultragenyx Pharmaceutical Inc
is
hidden
.
You don't have any saved screeners yet
